Evidence map›Paper›PMID 41605810›Full record

ArticleACS applied materials & interfaces2026

Hydroxycitrate is a Unique Inhibitor of Pathologically-Relevant Brushite Crystallization.

Dipayan Chakraborty, Muhammad Osman Khalid, Orson W Moe, Naim M Maalouf, Jeffrey D Rimer

Abstract read
In one paragraph

Article in ACS applied materials & interfaces, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dipayan ChakrabortyWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, 4226 Martin Luther King Blvd., Houston, Texas 77204-4004, United States.
Muhammad Osman KhalidWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, 4226 Martin Luther King Blvd., Houston, Texas 77204-4004, United States.
Orson W MoeDepartment of Internal Medicine, and Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8885, United States.
Naim M MaaloufDepartment of Internal Medicine, and Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8885, United States.
Jeffrey D RimerWilliam A. Brookshire Department of Chemical and Biomolecular Engineering, University of Houston, 4226 Martin Luther King Blvd., Houston, Texas 77204-4004, United States.ORCID 0000-0002-2296-3428

Funding

Hydroxycitrate: A Novel Therapy for Calcium Phosphate Urinary StonesR01DK136684 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI NAIM M MAALOUF · 2023 to 2026
$1.9M
NIDDK NIH HHS R01 DK136684
6 · The paper itself

Abstract

The unique interactions between (macro)molecules and the surfaces of crystalline materials is a common mechanism for controlling the formation of natural, biological, and synthetic crystals. These species, generally referred to as modifiers, can either inhibit or promote crystallization in ways that achieve properties unattainable by alternative processes, or alter nucleation to produce metastable polymorphs or solvates. In the field of pathological crystallization, modifiers can be native species or rationally designed molecules for the therapeutic purpose of suppressing crystal nucleation and/or growth. Here, we assess the effects of hydroxycitrate as a modifier of brushite (calcium phosphate dihydrate) crystallization and demonstrate its superior efficacy as an inhibitor compared to citrate, its molecular analogue present in urine naturally and commonly administered as a preventative therapy for calcium-based kidney stones. Using a combination of bulk crystallization, microfluidics, and atomic force microscopy, we show that hydroxycitrate is capable of completely suppressing brushite nucleation and operates as an effective growth inhibitor at concentrations nearly one order of magnitude lower than citrate. Our findings reveal a concentration-dependent mode of action for hydroxycitrate which at low supersaturation induces the formation of defects (i.e., surface voids) far from nucleation centers that are not observed at high supersaturation. Kinetic studies reveal that hydroxycitrate fully suppresses two of the three principal growth directions, whereas citrate only suppresses one direction. For crystallographic growth directions where modifiers are moderately effective, both citrate and hydroxycitrate inhibit crystallization by as much as 60%, leading to markedly reduced rates of growth and concomitant changes in crystal habit. Collectively, the results of this study open avenues into the design of potent inhibitors of pathological crystallization with potential implications for other biominerals.

Indexed as

Calcium PhosphatesCitratesCrystallizationMicroscopy, Atomic Forcecalcium phosphate, dibasic, dihydrateCalcium PhosphatesCitrateshydroxycitric acidatomic force microscopycalcium phosphatehydroxycitrateisobologramkink blockersmicrofluidicsnephrolithiasis

Identifiers

PMID41605810
PMCPMC13093249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.